Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03940820 |
TitleClinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | Phase
Phase 1/Phase 2
|
Date Added 2019-05-07 |
Location
China
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
ROBO1 CAR-NK cells |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03874897 |
TitleChimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. | Phase
Phase 1
|
Date Added 2019-03-14 |
Location
China
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06415851 |
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | Phase
Phase 2
|
Date Added 2024-05-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Phase
Phase 2
|
Date Added 2020-02-10 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04595266 |
TitleChemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | Phase
Phase 2
|
Date Added 2020-10-20 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02675946 |
TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Phase
Phase 1
|
Date Added 2016-02-05 |
Location
California, United States
Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Taiwan |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT03727763 |
TitleCetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) | Phase
Phase 2
|
Date Added 2018-11-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
cetuximab, Vemurafenib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05291156 |
TitleCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Phase
Phase 2
|
Date Added 2022-03-22 |
Location
Italy
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Avelumab, cetuximab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03297606 |
TitleCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Phase
Phase 2
|
Date Added 2017-09-29 |
Location
Canada
|
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05426005 |
TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-06-21 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Cadonilimab |
Tags
MSI-H/ MMRd
|
